4.6 Article

Heart Rate Reduction Improves Right Ventricular Function and Fibrosis in Pulmonary Hypertension

Journal

Publisher

AMER THORACIC SOC
DOI: 10.1165/rcmb.2019-0317OC

Keywords

right ventricle; pulmonary arterial hypertension; right ventricular pressure loading; heart rate; experimental

Funding

  1. Heart and Stroke Foundation of Canada [G-17-0018337]

Ask authors/readers for more resources

The potential benefit of heart rate reduction (HRR), independent of beta-blockade, on right ventricular (RV) function in pulmonary hypertension (PH) remains undecided. We studied HRR effects on RV fibrosis and function in PH and RV pressure-loading models. Adult rats were randomized to 1) sham controls, 2) monocrotaline (MCT)-induced PH, 3) SU5416 + hypoxia (SUHX)-induced PH, or 4) pulmonary artery banding (PAB). Ivabradine (IVA) (10 mg/kg/d) was administered from 2 weeks after PH induction or PAB. Exercise tolerance, echocardiography, and pressure-volume hemodynamics were obtained at a terminal experiment 3 weeks later. RV myocardial samples were analyzed for putative mechanisms of HRR effects through fibrosis, profibrotic molecular signaling, and Ca++ handling. The effects of IVA versus carvedilol on human induced pluripotent stem cell-derived cardiomyocytes beat rate and relaxation properties were evaluated in vitro. Despite unabated severely elevated RV systolic pressures, IVA improved RV systolic and diastolic function, profibrotic signaling, and RV fibrosis in PIT/PAB rats. RV systolic-elastance (control, 121 +/- 116; MCT, 49 +/- 36 vs. MCT+IVA, 120 +/- 54; PAB, 70 = 20 vs. PAB - IVA, 168 +/- 76; SUHX, 86 +/- 56 vs. SUHX +IVA, 218 +/- 111; all P < 0.05), the time constant of RV relaxation, echo indices of RV function, and fibrosis (fibrosis: control, 4.6 +/- 1%; MCT, 13.4 +/- 6.5 vs. MCT +IVA, 6.7 +/- 2.6%; PAB, 11.4 +/- 4.5 vs. PAB+IVA, 6.4 +/- 5.1%; SUHX, 10 +/- 4.6 vs. SUHX+IVA, 3.9 +/- 2.2%; all P <0.001) were improved by IVA versus controls. IVA had a dose-response effect on induced pluripotent stem cell-derived cardiomyocytes beat rate by delaying Ca++ loss from the cytoplasm. In experimental PH or RV pressure loading, HRR improves RV fibrosis, function, and exercise endurance independent of beta-blockade. The balance between adverse tachycardia and bradycardia requires further study, but judicious HRR may provide a promising strategy to improve RV function in clinical PH.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available